Tunable Half-Life Technology
BioProcess International Friday, March 1, 2013 9:00 am
Pub type: Veltis
"Addressing the half-life challenge has been a focus of industry product development in recent years. Real progress has been seen in development of technologies to modulate the serum half-lives of protein-based therapeutics to meet desired specifications. Increasing hydrophobic volume (through PEGylation, fusing proteins to polyethylene glycol molecules) and FcRn-mediated recycling (albumin fusion) are common strategies. Although both have been successful in extending serum half-life, researchers continue to work on specifically designing protein half-life to achieve desired pharmacokinetics."